Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
30 pending office actions • 19 art units • 29 examiners • 0 of 30 (0%) have an AI response strategy ready • 32 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 6 (20%) |
| §103 only | 6 (20%) |
| §112 only | 4 (13%) |
| Double-patenting + other | 2 (7%) |
| Multi-statute (no §101) | 11 (37%) |
| No statute on record | 1 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRETZ, COREY LANE | 2 | 0.0% | +0.0% |
| NGUYEN, HIEP VAN | 1 | 55.3% | +28.8% |
| GEMBEH, SHIRLEY V | 1 | 63.2% | +33.9% |
| LANKFORD JR, LEON B | 1 | 70.1% | +31.5% |
| WILDER, CYNTHIA B | 1 | 71.0% | +26.6% |
| BUNNER, BRIDGET E | 1 | 64.4% | +20.0% |
| ABOUELELA, MAY A | 1 | 75.2% | +36.3% |
| NG, JONATHAN K | 1 | 35.6% | +13.4% |
| KENYON, JOHN S | 1 | 79.9% | +18.0% |
| HINES, JANA A | 1 | 53.1% | +39.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17435159 | ANTI-CD38 AGENTS FOR DESENSITIZATION AND TREATMENT OF ANTIBODY-MEDIATED REJECTION OF ORGAN TRANSPLANTS | STONEBRAKER, ALYSSA RAE | 31d overdue |
| 18350077 | METHODS AND FORMULATIONS FOR GENE THERAPY, AND FOR COMBINING GENE THERAPY WITH DITPA TREATMENT, OF ALLAN-HERNDON-DUDLEY SYNDROME | BRETZ, COREY LANE | 6d |
| 19123191 | METHODS AND SYSTEMS OF MULTI-OMIC APPROACH FOR MOLECULAR PROFILING OF TUMORS | NGUYEN, HIEP VAN | — |
| 18852803 | METHODS OF DIAGNOSING IBS-D AND SELECTION OF IBS-D TREATMENT | LANKFORD JR, LEON B | — |
| 18647340 | RADIOGENOMIC SIGNATURES IN BLADDER CANCER PATIENTS AND USES THEREOF | WILDER, CYNTHIA B | — |
| 18645261 | HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF | BUNNER, BRIDGET E | — |
| 18695144 | DAILY FASTING METHANE TO DETECT INTESTINAL METHANOGEN OVERGROWTH AND MONITOR TREATMENT RESPONSE | ABOUELELA, MAY A | — |
| 18580962 | METHODS AND SYSTEMS FOR EARLY DETECTION OF OCULAR AND/OR NEUROLOGICAL CONDITIONS | NG, JONATHAN K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18530467 | COMPOUNDS AND METHODS TO SENSITIZE CANCER CELLS TO TYROSINE KINASE INHIBITORS | KENYON, JOHN S | 34d |
| 19123191 | METHODS AND SYSTEMS OF MULTI-OMIC APPROACH FOR MOLECULAR PROFILING OF TUMORS | NGUYEN, HIEP VAN | — |
| 18862311 | RIFAXIMIN AND N-ACETYL CYSTEINE FORMULATIONS | GEMBEH, SHIRLEY V | — |
| 18852803 | METHODS OF DIAGNOSING IBS-D AND SELECTION OF IBS-D TREATMENT | LANKFORD JR, LEON B | — |
| 18647340 | RADIOGENOMIC SIGNATURES IN BLADDER CANCER PATIENTS AND USES THEREOF | WILDER, CYNTHIA B | — |
| 18645261 | HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF | BUNNER, BRIDGET E | — |
| 18695144 | DAILY FASTING METHANE TO DETECT INTESTINAL METHANOGEN OVERGROWTH AND MONITOR TREATMENT RESPONSE | ABOUELELA, MAY A | — |
| 18580962 | METHODS AND SYSTEMS FOR EARLY DETECTION OF OCULAR AND/OR NEUROLOGICAL CONDITIONS | NG, JONATHAN K | — |
| Art Unit | Apps |
|---|---|
| 3791 | 2 |
| 3619 | 2 |
| 1645 | 2 |
| 1682 | 2 |
| 1634 | 2 |
| 1642 | 2 |
| 3686 | 1 |
| 1625 | 1 |
| 1635 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19123191 | METHODS AND SYSTEMS OF MULTI-OMIC APPROACH FOR MOLECULAR PROFILING OF TUMORS | NGUYEN, HIEP VAN | 3686 | §101§103§112 | Non-Final OA | — | Pending | Apr 22, 2025 |
| 18862311 | RIFAXIMIN AND N-ACETYL CYSTEINE FORMULATIONS | GEMBEH, SHIRLEY V | — | §103 | Non-Final OA | — | Pending | Nov 01, 2024 |
| 18852803 | METHODS OF DIAGNOSING IBS-D AND SELECTION OF IBS-D TREATMENT | LANKFORD JR, LEON B | — | §102§103 | Non-Final OA | — | Pending | Sep 30, 2024 |
| 18647340 | RADIOGENOMIC SIGNATURES IN BLADDER CANCER PATIENTS AND USES THEREOF | WILDER, CYNTHIA B | — | §103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18645261 | HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF | BUNNER, BRIDGET E | — | §102§112Other | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18695144 | DAILY FASTING METHANE TO DETECT INTESTINAL METHANOGEN OVERGROWTH AND MONITOR TREATMENT RESPONSE | ABOUELELA, MAY A | 3791 | §101§103§112 | Non-Final OA | — | Pending | Mar 25, 2024 |
| 18580962 | METHODS AND SYSTEMS FOR EARLY DETECTION OF OCULAR AND/OR NEUROLOGICAL CONDITIONS | NG, JONATHAN K | 3619 | §101§103 | Final Rejection | — | Pending | Jan 19, 2024 |
| 18571924 | THERAPEUTIC NUCLEIC ACIDS AND METHODS OF USE THEREOF | BRETZ, COREY LANE | — | §101§102§103§112DP | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18530467 | COMPOUNDS AND METHODS TO SENSITIZE CANCER CELLS TO TYROSINE KINASE INHIBITORS | KENYON, JOHN S | 1625 | Other | Non-Final OA | 34d | Pending | Dec 06, 2023 |
| 18386537 | METHODS FOR TREATING NEPHROTIC SYNDROME | HINES, JANA A | 1645 | §103§112 | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18235945 | ENDOSCOPIC FLUID ASPIRATION DEVICE | YOON, CHANEL J | 3791 | §103 | Non-Final OA | 60d overdue | Pending | Aug 21, 2023 |
| 18546947 | ANTI-TL1A ANTIBODY COMPOSITIONS AND METHODS OF TREATMENT IN THE LUNG | STEPHENS, AMELIA CAROLE | 1645 | §103DP | Final Rejection | 50d | Pending | Aug 17, 2023 |
| 18350077 | METHODS AND FORMULATIONS FOR GENE THERAPY, AND FOR COMBINING GENE THERAPY WITH DITPA TREATMENT, OF ALLAN-HERNDON-DUDLEY SYNDROME | BRETZ, COREY LANE | 1635 | §103§112DP | Final Rejection | 6d | Pending | Jul 11, 2023 |
| 18326912 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | HUDSON, AMY ROSE | 1636 | §112 | Final Rejection | 46d | Pending | May 31, 2023 |
| 18310796 | METHODS FOR TREATING SHORT BOWEL SYNDROME AND/OR HIGH OUTPUT OSTOMY | VU, JAKE MINH | 1618 | §102§103§112Other | Non-Final OA | — | Pending | May 02, 2023 |
| 18008146 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | GOLDBERG, JEANINE ANNE | 1682 | §101§112DP | Non-Final OA | — | Pending | Dec 02, 2022 |
| 17924010 | DEVICES, ASSAYS AND METHODS OF TESTING PREECLAMPSIA | GIERE, REBECCA M | 1677 | §102§103§112 | Non-Final OA | — | Pending | Nov 08, 2022 |
| 17921217 | MULTI-LINEAGE CARDIOVASCULAR MICROFLUIDIC ORGAN-CHIP | DHAR, MATASHA | 1632 | §102§103§112 | Non-Final OA | — | Pending | Oct 25, 2022 |
| 17921174 | ISOLATION AND FUNCTIONAL ANALYSIS OF EPITHELIAL PROGENITOR CELLS FROM THE HUMAN LUNG | ABBOTT, KODYE LEE | 1634 | §103§112 | Final Rejection | — | Pending | Oct 25, 2022 |
| 17912809 | INTERNAL ULTRAVIOLET THERAPY | HOLMES, REX R | 3796 | §103 | Non-Final OA | — | Pending | Sep 19, 2022 |
| 17779716 | COMPOSITIONS AND METHODS FOR TREATING DISEASES AND CONDITIONS BY DEPLETION OF MITOCHONDRIAL OR GENOMIC DNA FROM CIRCULATION | AEDER, SEAN E | 1642 | §102§103§112 | Final Rejection | — | Pending | May 25, 2022 |
| 17633505 | METHOD OF GENERATING ACTIVATED T CELLS FOR CANCER THERAPY | WEHBE, ANNE MARIE SABRINA | 1634 | §103 | Final Rejection | — | Pending | Feb 07, 2022 |
| 17633067 | METHODS OF IMPROVING ORGAN FUNCTION | AUDET, MAURY A | 1654 | §112 | Final Rejection | — | Pending | Feb 04, 2022 |
| 17565834 | METHODS OF DIAGNOSIS, SELECTION, AND TREATMENT OF DISEASES AND CONDITIONS CAUSED BY OR ASSOCIATED WITH METHANOGENS | FERNANDEZ, SUSAN EMILY | 1651 | §112 | Final Rejection | 112d overdue | Pending | Dec 30, 2021 |
| 17435159 | ANTI-CD38 AGENTS FOR DESENSITIZATION AND TREATMENT OF ANTIBODY-MEDIATED REJECTION OF ORGAN TRANSPLANTS | STONEBRAKER, ALYSSA RAE | 1642 | §102§103§112 | Non-Final OA | 31d overdue | Pending | Aug 31, 2021 |
| 17334109 | METHODS OF STRATIFYING AND TREATING A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | WHALEY, PABLO S | 3619 | §112 | Final Rejection | 20d | Pending | May 28, 2021 |
| 17266488 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND AUTOIMMUNE DISEASES | LADD, CAROLYN LOUISE | 1622 | §103Other | Final Rejection | 56d | Pending | Feb 05, 2021 |
| 17043888 | METHODS FOR IN VITRO EXPANSION OF ADULT TISSUE STEM CELLS | GONZALES, JOSEPHINE MARIA | 1631 | §103 | Non-Final OA | — | Pending | Sep 30, 2020 |
| 16832977 | GUT BACTERIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND METHODS THEREWITH IN DETECTING ILEAL FIBROSIS | SITTON, JEHANNE SOUAYA | 1682 | §103§112 | Non-Final OA | — | Pending | Mar 27, 2020 |
| 16515458 | HIGHLY MULTIPLEXED AND MASS SPECTROMETRY BASED METHODS TO MEASURING 72 HUMAN PROTEINS | MARTIN, PAUL C | 1653 | §101§103§112 | Non-Final OA | — | Pending | Jul 18, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial